The company shared its second quarter financial results along with updates on its operations.
“Our strategy to transform Aziyo into a high growth drug-eluting biomatrix product company continues to move forward,” CEO Randy Mills, PhD, said in a news release. “We are in discussions with several interested parties to divest our orthopedics business.”
Net sales in the second quarter were $10.3 million, down from $12.6 million in the same time last year. The decrease was largely due to a viable bone matrix recall, which led to a reversal of $3 million in second quarter revenue.
